Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the path
Our site uses cookies and similar technologies to offer you a better experience. We use analytical cookies (our own and third party) to understand and improve your browsing experience, and advertising cookies (our own and third party) to send you advertisements in line with your preferences. To modify or opt-out of the use of some or all of our cookies, please go to “Manage Cookies” or view our Cookie Policy to find out more. By clicking “Accept all” you consent to the use of these cookies.
